Editas Medicine· @editasmed · X·· 2026-05-28AI 评分18
AI 导读
本周早些时候，在 #EASCongress2026 上，我们展示了新的临床前数据，支持我们领先的体内开发候选药物 EDIT-401 的持续推进。在此查看新闻稿：https://bit.ly/4agcD3R。#invivo #geneediting #cardiovasculardisease
正文
At #EASCongress2026 earlier this week, we presented new preclinical data supporting the continued advancement of our lead in vivo development candidate, EDIT-401. View the press release here: https://bit.ly/4agcD3R. #invivo #geneediting #cardiovasculardisease
来源：Editas Medicine · x.com